RT001: Preliminary Phase I/II data

Preliminary data from a double-blind U.S. Phase I/II trial in 18 patients with Friedreich’s ataxia showed that once-daily 1.8 g oral RT001 and twice-daily 4.5 g oral RT001 given for 28 days were well ...